In a phase II study of 23 patients with recurrent GBM and 11 patients with newly diagnosed GBM receiving tumor lysate-pulsed DCs, 50% of patients had positive vaccine responses as indicated by a 1.5 or more fold enhancement of IFN-gamma production compared to pre-vaccination levels. The gene discussed is IFNG; the disease is glioblastoma.